Comparing Machine Learning and Advanced Methods with Traditional Methods to Generate Weights in Inverse Probability of Treatment Weighting: The INFORM Study [0.03%]
基于机器学习和改进方法与传统方法在逆概率治疗加权中生成权重的比较研究(INFORM研究)
Doyoung Kwak,Yuanjie Liang,Xu Shi et al.
Doyoung Kwak et al.
Purpose: Observational research provides valuable insights into treatments used in patient populations in real-world settings. However, confounding is likely to occur if there are differences in patient characteristics as...
Involvement of Root Canal Treatment in Pro-Inflammatory Processes - A Real-World Study [0.03%]
根管治疗在促炎过程中的作用——一项真实世界研究
Joé Diederich,Kurt E Müller
Joé Diederich
Purpose: Endodontic inflammation typically results from root canal infections and sensitizations to filling materials after root canal treatment (RCT), potentially leading to systemic inflammation and disease. We therefor...
UK Electronic Healthcare Records for Research: A Scientometric Analysis of Respiratory, Cardiovascular, and COVID-19 Publications [0.03%]
英国电子健康记录在科研中的应用——基于呼吸系统、心血管疾病以及新冠领域文献的科学计量分析
Georgie M Massen,Olivia Blamires,Megan Grainger et al.
Georgie M Massen et al.
Background: Routinely collected electronic healthcare records (EHRs) document many details of a person's health, including demographics, preventive services, symptoms, tests, disease diagnoses and prescriptions. Although ...
Therapeutic Advances in Obesity: How Real-World Evidence Impacts Affordability Beyond Standard of Care [0.03%]
肥胖症的治疗进展：真实世界证据如何影响标准护理之外的可负担性问题
Dimitrios Patoulias,Theocharis Koufakis,Ieva Ruža et al.
Dimitrios Patoulias et al.
Obesity is currently considered a global epidemic, with rising prevalence worldwide and rather pessimistic projections. Based on its close interconnection with various co-morbidities, such as diabetes mellitus and cardiovascular disease, ob...
A Real-World Study on the Short-Term Efficacy of Amlodipine in Treating Hypertension Among Inpatients [0.03%]
氨氯地平治疗住院高血压患者短期疗效的现实世界研究
Tingting Wang,Juntao Tan,Tiantian Wang et al.
Tingting Wang et al.
Purpose: Hospitalized hypertensive patients rely on blood pressure medication, yet there is limited research on the sole use of amlodipine, despite its proven efficacy in protecting target organs and reducing mortality. T...
Quality of Life in Patients Affected by Facial Basal Cell Carcinoma: Prospective Longitudinal Pilot Study and Validation of Skin Cancer Index in Lithuanian Language [0.03%]
面部基底细胞癌患者的生存质量：前瞻性纵向试点研究及皮肤癌症指数立陶宛语版本的验证
Domantas Stundys,Alvija Kučinskaitė,Simona Gervickaitė et al.
Domantas Stundys et al.
Purpose: Facial basal cell carcinoma (BCC) poses significant challenges due to its potential for local destruction and impact on quality of life (QoL). Continuous research is necessary to identify novel factors influencin...
Advanced Multi-Layer Watertight Closure versus Conventional Closure in Total Hip and Knee Replacement Surgery [0.03%]
髓外多层防水缝合与传统缝合在全髋和全膝关节置换术中的应用研究
Jana L Flener,Brian Po-Han Chen,Frank R Ernst et al.
Jana L Flener et al.
Background: In total joint replacement procedures, surgeons have increasingly adopted advanced multi-layer, watertight closure. The objective of the study was to compare the clinical and economic outcomes for advanced mul...
Critique on "Real-World Effectiveness of First-Line Lenvatinib Therapy in Advanced Hepatocellular Carcinoma: Current Insights" [Response to Letter] [0.03%]
关于“索拉非尼一线治疗后使用乐伐替尼治疗晚期肝细胞癌的现实世界有效性”论文的评论[对来信的回复]
Tiago Biachi de Castria,Richard D Kim
Tiago Biachi de Castria
Critique on "Real-World Effectiveness of First-Line Lenvatinib Therapy in Advanced Hepatocellular Carcinoma: Current Insights" [Letter] [0.03%]
关于“仑伐替尼一线治疗晚期肝细胞癌真实世界有效性现况展望”的点评[信]
Manjeet Kumar Goyal,Manisha Khubber,Varun Mehta
Manjeet Kumar Goyal
Real-World Effectiveness of First Line Lenvatinib Therapy in Advanced Hepatocellular Carcinoma: Current Insights [0.03%]
仑伐替尼一线治疗晚期肝细胞癌的现实世界疗效：当前的认识水平
Tiago Biachi de Castria,Richard D Kim
Tiago Biachi de Castria
Lenvatinib received its initial approval in 2018 for the treatment of advanced hepatocellular carcinoma. It has since emerged as the preferred first line agent, supported by non-inferiority data from the REFLECT trial. Notably, lenvatinib e...